Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORAGER-2: Vepugratinib + EV + Pembrolizumab in Untreated Advanced Urothelial Carcinoma
NCT07218380Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of vepugratinib in urothelial carcinoma (UC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab at 90 months, Overall Response Rate at 90 months and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
vepugratinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07218380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218380.